US 11,938,198 B2
Treatment of heart disease by disruption of the anchoring of PP2A
Michael S. Kapiloff, Los Altos, CA (US); and Jinliang Li, Palo Alto, CA (US)
Assigned to University of Miami, Miami, FL (US); and The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed by University of Miami, Miami, FL (US); and The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed on Mar. 13, 2020, as Appl. No. 16/818,771.
Claims priority of provisional application 62/848,156, filed on May 15, 2019.
Prior Publication US 2020/0360536 A1, Nov. 19, 2020
Prior Publication US 2022/0008560 A2, Jan. 13, 2022
Int. Cl. A61K 48/00 (2006.01); A61K 35/761 (2015.01); A61P 9/04 (2006.01)
CPC A61K 48/0066 (2013.01) [A61K 35/761 (2013.01); A61P 9/04 (2018.01)] 10 Claims
 
1. A composition comprising a nucleic acid that encodes a molecule consisting of amino acids 2132-2319 of human mAKAP, wherein said molecule inhibits the-dephosphorylation activity of protein (serine-threonine) phosphatase 2A (PP2A) resulting in a maintained level of phosphorylation on serum response factor (SRF).